{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T09:03:23Z","timestamp":1790240603911,"version":"4.1.0"},"reference-count":25,"publisher":"Wiley","issue":"4","license":[{"start":{"date-parts":[[2017,4,17]],"date-time":"2017-04-17T00:00:00Z","timestamp":1492387200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"funder":[{"DOI":"10.13039\/501100005010","name":"Associazione Italiana per la Ricerca sul Cancro","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100005010","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Br J Haematol"],"published-print":{"date-parts":[[2017,5]]},"abstract":"<jats:title>Summary<\/jats:title><jats:p><jats:italic><jats:styled-content style=\"fixed-case\">BCL<\/jats:styled-content>2\/<jats:styled-content style=\"fixed-case\">IGH<\/jats:styled-content><\/jats:italic> rearrangements were analysed by polymerase chain reaction (<jats:styled-content style=\"fixed-case\">PCR<\/jats:styled-content>) at diagnosis in paired peripheral blood (<jats:styled-content style=\"fixed-case\">PB<\/jats:styled-content>) and bone marrow (<jats:styled-content style=\"fixed-case\">BM<\/jats:styled-content>) samples from 67 patients with stage I\/<jats:styled-content style=\"fixed-case\">II<\/jats:styled-content> follicular lymphoma (<jats:styled-content style=\"fixed-case\">FL<\/jats:styled-content>). Real time quantitative <jats:styled-content style=\"fixed-case\">PCR<\/jats:styled-content> (<jats:styled-content style=\"fixed-case\">RQ<\/jats:styled-content>\u2010<jats:styled-content style=\"fixed-case\">PCR<\/jats:styled-content>) and digital droplet <jats:styled-content style=\"fixed-case\">PCR<\/jats:styled-content> (dd<jats:styled-content style=\"fixed-case\">PCR<\/jats:styled-content>) were performed in cases with a major breakpoint region (MBR+) at diagnosis and after localized radiotherapy and rituximab administration in order to investigate the applicability of dd<jats:styled-content style=\"fixed-case\">PCR<\/jats:styled-content>. The overall dd<jats:styled-content style=\"fixed-case\">PCR<\/jats:styled-content>\/<jats:styled-content style=\"fixed-case\">RQ<\/jats:styled-content>\u2010<jats:styled-content style=\"fixed-case\">PCR<\/jats:styled-content> concordance was 81\u00b79% (113\/138 samples) and 97\u00b75% in the 40\/138 with quantifiable disease (<jats:styled-content style=\"fixed-case\">RQ<\/jats:styled-content>\u2010<jats:styled-content style=\"fixed-case\">PCR<\/jats:styled-content>\u226510<jats:sup>\u22125<\/jats:sup>). At baseline, dd<jats:styled-content style=\"fixed-case\">PCR<\/jats:styled-content> allowed the recovery of a MBR+ marker in 8\/18 (44\u00b74%) samples that resulted MBR\u2010negative\/minor cluster region\u2010negative\/minor <jats:italic>BCL2<\/jats:italic>\u2010negative by qualitative <jats:styled-content style=\"fixed-case\">PCR<\/jats:styled-content>. Moreover, the tumour burden at diagnosis significantly predicted progression\u2010free survival (<jats:styled-content style=\"fixed-case\">PSF<\/jats:styled-content>) only when quantified by dd<jats:styled-content style=\"fixed-case\">PCR<\/jats:styled-content>. Paired <jats:styled-content style=\"fixed-case\">PB<\/jats:styled-content> and <jats:styled-content style=\"fixed-case\">BM<\/jats:styled-content> samples analysis demonstrated a high concordance in the detection of <jats:italic><jats:styled-content style=\"fixed-case\">BCL<\/jats:styled-content>2\/IGH+<\/jats:italic> cells by qualitative and quantitative methods; in particular, 40\/62 samples were positive by dd<jats:styled-content style=\"fixed-case\">PCR<\/jats:styled-content> (25 PB+\/BM+; 9 PB+\/BM\u2212; 6 PB\u2212\/BM+), with 34\/40 (85%) identified by the study of <jats:styled-content style=\"fixed-case\">PB<\/jats:styled-content> only. In conclusion, in localized <jats:styled-content style=\"fixed-case\">FL<\/jats:styled-content>, dd<jats:styled-content style=\"fixed-case\">PCR<\/jats:styled-content> is a promising tool for monitoring minimal residual disease (MRD) that is at least comparable to <jats:styled-content style=\"fixed-case\">RQ<\/jats:styled-content>\u2010<jats:styled-content style=\"fixed-case\">PCR<\/jats:styled-content> and potentially more accurate. <jats:styled-content style=\"fixed-case\">PB<\/jats:styled-content> is a suitable source for serial <jats:italic><jats:styled-content style=\"fixed-case\">BCL<\/jats:styled-content>2\/<jats:styled-content style=\"fixed-case\">IGH<\/jats:styled-content><\/jats:italic> <jats:styled-content style=\"fixed-case\">MRD<\/jats:styled-content> assessments, regardless of the methodology utilized.<\/jats:p>","DOI":"10.1111\/bjh.14616","type":"journal-article","created":{"date-parts":[[2017,4,17]],"date-time":"2017-04-17T10:26:48Z","timestamp":1492424808000},"page":"588-596","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":41,"title":["Comparative analysis between <scp>RQ<\/scp>\u2010<scp>PCR<\/scp> and digital droplet <scp>PCR<\/scp> of <i><scp>BCL<\/scp>2\/<scp>IGH<\/scp><\/i> gene rearrangement in the peripheral blood and bone marrow of early stage follicular lymphoma"],"prefix":"10.1111","volume":"177","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2773-5483","authenticated-orcid":false,"given":"Marzia","family":"Cavalli","sequence":"first","affiliation":[{"name":"Haematology Department of Cellular Biotechnologies and Haematology Policlinico Umberto I Sapienza University Rome Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lucia Anna","family":"De Novi","sequence":"additional","affiliation":[{"name":"Haematology Department of Cellular Biotechnologies and Haematology Policlinico Umberto I Sapienza University Rome Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Irene","family":"Della Starza","sequence":"additional","affiliation":[{"name":"Haematology Department of Cellular Biotechnologies and Haematology Policlinico Umberto I Sapienza University Rome Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luca Vincenzo","family":"Cappelli","sequence":"additional","affiliation":[{"name":"Haematology Department of Cellular Biotechnologies and Haematology Policlinico Umberto I Sapienza University Rome Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vittorio","family":"Nunes","sequence":"additional","affiliation":[{"name":"San Gerardo Hospital Fondazione Matilde Tettamanti Menotti De Marchi Onlus Monza Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessandro","family":"Pulsoni","sequence":"additional","affiliation":[{"name":"Haematology Department of Cellular Biotechnologies and Haematology Policlinico Umberto I Sapienza University Rome Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ilaria","family":"Del Giudice","sequence":"additional","affiliation":[{"name":"Haematology Department of Cellular Biotechnologies and Haematology Policlinico Umberto I Sapienza University Rome Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna","family":"Guarini","sequence":"additional","affiliation":[{"name":"Haematology Department of Cellular Biotechnologies and Haematology Policlinico Umberto I Sapienza University Rome Italy"},{"name":"Department of Molecular Medicine Sapienza University Rome Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robin","family":"Fo\u00e0","sequence":"additional","affiliation":[{"name":"Haematology Department of Cellular Biotechnologies and Haematology Policlinico Umberto I Sapienza University Rome Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2017,4,17]]},"reference":[{"key":"e_1_2_8_2_1","doi-asserted-by":"publisher","DOI":"10.18632\/oncotarget.3773"},{"key":"e_1_2_8_3_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ymeth.2012.08.001"},{"key":"e_1_2_8_4_1","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.14082"},{"key":"e_1_2_8_5_1","doi-asserted-by":"publisher","DOI":"10.1038\/sj.leu.2403202"},{"key":"e_1_2_8_6_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jmoldx.2015.05.007"},{"key":"e_1_2_8_7_1","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-14-0407"},{"key":"e_1_2_8_8_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199111283252201"},{"key":"e_1_2_8_9_1","doi-asserted-by":"crossref","first-page":"1355","DOI":"10.5858\/2008-132-1355-PDOBIF","article-title":"Practical detection of t(14;18)(IgH\/BCL2) in follicular lymphoma","volume":"132","author":"Gu K.","year":"2008","journal-title":"Archives of Pathology and Laboratory Medicine"},{"key":"e_1_2_8_10_1","doi-asserted-by":"publisher","DOI":"10.1021\/ac202028g"},{"key":"e_1_2_8_11_1","doi-asserted-by":"publisher","DOI":"10.1038\/nmeth.2633"},{"key":"e_1_2_8_12_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2141.2008.07101.x"},{"key":"e_1_2_8_13_1","doi-asserted-by":"publisher","DOI":"10.1373\/clinchem.2013.214742"},{"key":"e_1_2_8_14_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0085999"},{"key":"e_1_2_8_15_1","doi-asserted-by":"publisher","DOI":"10.1038\/nri2217"},{"key":"e_1_2_8_16_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0301-472X(00)00651-2"},{"key":"e_1_2_8_17_1","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2015.330"},{"key":"e_1_2_8_18_1","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.25149"},{"key":"e_1_2_8_19_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2141.2007.06545.x"},{"key":"e_1_2_8_20_1","doi-asserted-by":"crossref","first-page":"2959","DOI":"10.1182\/blood.V128.22.2959.2959","article-title":"Early stage follicular lymphoma. Predictive role of minimal residual disease (MRD) and impact of MRD\u2010driven treatment with radiotherapy and rituximab on clinical outcome","volume":"128","author":"Pulsoni A.","year":"2016","journal-title":"Blood"},{"key":"e_1_2_8_21_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2004-06-2490"},{"key":"e_1_2_8_22_1","doi-asserted-by":"publisher","DOI":"10.1038\/sj.leu.2404035"},{"key":"e_1_2_8_23_1","doi-asserted-by":"publisher","DOI":"10.1172\/JCI72415"},{"key":"e_1_2_8_24_1","doi-asserted-by":"publisher","DOI":"10.1038\/sj.leu.2404586"},{"key":"e_1_2_8_25_1","doi-asserted-by":"publisher","DOI":"10.1038\/sj.bmt.1701300"},{"key":"e_1_2_8_26_1","doi-asserted-by":"publisher","DOI":"10.2353\/jmoldx.2007.070038"}],"container-title":["British Journal of Haematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fbjh.14616","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/bjh.14616","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,3]],"date-time":"2023-10-03T06:50:45Z","timestamp":1696315845000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/bjh.14616"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,4,17]]},"references-count":25,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2017,5]]}},"alternative-id":["10.1111\/bjh.14616"],"URL":"https:\/\/doi.org\/10.1111\/bjh.14616","archive":["Portico"],"relation":{},"ISSN":["0007-1048","1365-2141"],"issn-type":[{"value":"0007-1048","type":"print"},{"value":"1365-2141","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,4,17]]},"assertion":[{"value":"2016-09-28","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2016-12-31","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2017-04-17","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}